Top 60+ Pharmaceutical Companies In Florida In 2021
← Visit blog

Top 60+ Pharmaceutical Companies In Florida In 2021

Updated on March 11th, 2021

Top 60+ Pharmaceutical Companies In Florida In 2021

A hand curated list of 60+ top pharmaceutical companies in Florida.
Whether you run a digital agency, a B2B company, or just want to connect with fast growing companies, this is the list for you.
In our premium lists, we also include: • 20+ data points for each company
• Services they’re likely to outsource
• CEO Information & Email
If you’re interested in our premium lists, consider subscribing to our monthly report of tech companies.


Table Of Contents

  1. KemPharm ($10M to $50M)
  2. GENELINK ($10M to $50M)
  3. Cognition Health Partners ($10M to $50M)
  4. Kirax (Less than $1M)
  5. Catalyst Pharmaceuticals Partners ($10M to $50M)
  6. Biscayne NeuroTherapeutics (Less than $1M)
  7. Applied Genetics Technologies Corporation ($10M to $50M)
  8. RCT Logic ($10M to $50M)
  9. Tigris Pharmaceuticals ($10M to $50M)
  10. CoreRx ($10M to $50M)
  11. Tissuetech ($50M to $100M)
  12. Oragenics (Less than $1M)
  13. Accudial Pharmaceutical ($10M to $50M)
  14. Altor BioScience ($10M to $50M)
  15. Dyadic International (Less than $1M)
  16. Ascendx Spine (Less than $1M)
  17. Sensus Healthcare ($1M to $10M)
  18. Integrity Implants (Less than $1M)
  19. Procera ($10M to $50M)
  20. Halodine ($10M to $50M)
  21. Taronis Technologies ($1M to $10M)
  22. Envoy Therapeutics (Less than $1M)
  23. Variant Pharmaceuticals (Less than $1M)
  24. NeoGenomics Laboratories ($100M to $500M)
  25. BioMatrix Specialty Pharmacy ($1M to $10M)
  26. Lakewood Amedex ($10M to $50M)
  27. BlinkBio ($1M to $10M)
  28. Quantitative Medicine (Less than $1M)
  29. Cantex Pharmaceuticals ($10M to $50M)
  30. Coqui Radio Pharmaceuticals (Less than $1M)
  31. VaxCare ($10M to $50M)
  32. Cyclo Therapeutics (Less than $1M)
  33. Sincerus Pharmaceuticals ($10M to $50M)
  34. Vector Vitale ($10M to $50M)
  35. Progressive Care ($10M to $50M)
  36. American Injectables (Less than $1M)
  37. Accentia Biopharmaceuticals Inc ($10M to $50M)
  38. Health Integrated (Less than $1M)
  39. Binder Biomedical (Less than $1M)
  40. Generex Biotechnology (Less than $1M)
  41. Dermal Life (Less than $1M)
  42. MailMyPrescriptions.com (Less than $1M)
  43. Evolugate ($10M to $50M)
  44. inCyte Innovations ($10M to $50M)
  45. Nanotherapeutics ($10M to $50M)
  46. Veloce BioPharma ($1M to $10M)
  47. Biscayne Pharmaceuticals ($1M to $10M)
  48. Jupiter Orphan Therapeutics ($1M to $10M)
  49. myMatrixx ($10M to $50M)
  50. UNO HEALTHCARE ($10M to $50M)
  51. American Clinical Solutions ($1M to $10M)
  52. Accu-Break Pharmaceuticals ($1M to $10M)
  53. Hansen Pharmaceutical (Less than $1M)
  54. BioCurity Pharmaceuticals (Less than $1M)
  55. Diverse Biotech (Less than $1M)
  56. Enalare Therapeutics (Less than $1M)
  57. Rothman Healthcare (Less than $1M)
  58. TherapeuticsMD ($10M to $50M)
  59. Nuovo Biologics (Less than $1M)
  60. OPKO Health ($100M to $500M)
  61. Sancilio and Company ($1M to $10M)
  62. Romark Laboratories ($10M to $50M)
  63. MATINAS BIOPHARMA ($1B to $10B)
  64. RIST Neurovascular (Less than $1M)
  65. Renibus Therapeutics ($10M to $50M)
  66. Teewinot Life Sciences (Less than $1M)
  67. Trxade Group ($1M to $10M)


  1. KemPharm ($10M to $50M)

    KemPharm is a development-stage biopharmaceutical company focused on the discovery and development of new, safer therapies in the areas of pain, ADHD, and other CNS diseases. The company’s primary efforts include the development of safer, abuse-resistant opioid pain relievers. Its drug discovery and development platform is based on its proprietary Ligand Activated Therapy (LAT) approach. KemPharm uses its patent-applied technology to improve existing drugs and shorten the development timeline while still maintaining a strong intellectual property position within each therapeutic area.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $4M raised in March, 2015
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  2. people sitting on black chairs




  3. Cognition Health Partners ($10M to $50M)

    Health Information Services with a focus on enabling providers to meet current and future documentation requirements while enhancing workflow efficiency. Exchanging clinical data between providers is key for advancing initiatives for improving the health care delivery model. Enabling providers to achieve better outcomes, driving down the cost of acute care, enabling healthcare communities to implement ACO's and helping employers establish preventive health programs are all part of CHP's solutions.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $1.6M raised in September, 2012
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  4. rolling armchair beside table


  5. Kirax (Less than $1M)

    Kirax Corporation, a biopharmaceutical company, engages in acquiring, developing, and commercializing specialty care therapies to treat oncology, pain, inflammation, acute, and supportive care areas of unmet medical need. Its product pipeline includes AFP-464, an anti-cancer agent in patients with breast cancer; GGTI-2418, a synthetic peptidomimetic inhibitor of geranylgeranyltransferase I (GGTase I) that appears to induce apoptosis by down-regulating several pivotal oncogenic and tumor survival pathways; and GFB-204, a calixarene derivative that is an inhibitor of VEGFR and PDGFR tyrosine phosphorylation. The company licenses or acquires rights to compounds in various stages of clinical development, as well as in-market products. Kirax Corporation was formerly known as Tigris Pharmaceuticals, Inc. The company was founded in 2005 and is based in Bonita Springs, Florida.

    • Less than $1M annual revenues
    • 1-10 employees
    • $0.5M raised in September, 2012
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  6. people sitting on chairs near tables during daytime


  7. Catalyst Pharmaceuticals Partners ($10M to $50M)

    Catalyst is a specialty pharmaceutical company focused on the development and commercialization of prescription drugs targeting rare (orphan) neuromuscular and neurological diseases, including Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms and Tourette's disorder. Catalyst is developing Firdapse™ (Amifampridine Phosphate, or 3,4-diaminopyridine phosphate) for the treatment of LEMS, a rare neuromuscular, autoimmune disorder frequently associated with small cell lung cancer. Catalyst also believes that Firdapse™ has the potential to treat other neuromuscular disorders such as congenital myasthenic syndrome and some cases of myasthenia gravis that are refractory to currently approved therapies.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $15.1M raised in September, 2013
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  8. people standiunmg


  9. Biscayne NeuroTherapeutics (Less than $1M)

    Biscayne Neurotherapeutics is a clinical-stage biotechnology company developing novel therapies for difficult-to-treat neurological disorders. Biscayne’s lead compound, BIS-001, is in clinical development for the treatment of refractory forms of epilepsy. Biscayne Neurotherapeutics has an experienced executive team with an extensive track record of successful drug development, and its scientific advisors include a number of highly respected experts studying seizure and other CNS disorders. The company is headquartered in Miami, Florida, and benefits from the growing entrepreneurial South Florida biomedical sector.

    • Less than $1M annual revenues
    • 1-10 employees
    • $3M raised in January, 2017
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  10. people having meeting on rectangular brown table


  11. Applied Genetics Technologies Corporation ($10M to $50M)

    Applied Genetics Technologies Corporation (AGTC) is developing therapies designed to transform the lives of patients with severe diseases, offering hope to patients with unmet medical needs. With a highly specialized team of physicians and researchers, They use cutting-edge techniques to develop treatments for patients that have diseases caused by broken genes. They use gene therapy, which replaces those broken genes with normal functional genes, allowing a patient’s own body to produce proteins to treat their illness. A single injection provides long-lasting treatment, leading to a better quality of life for patients worldwide.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $74.5M raised in January, 2021
    • 5 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  12. people using desktop computer inside office


  13. RCT Logic ($10M to $50M)

    RCT Logic LLC develops and licenses clinical trial designs for use in trials sponsored by industry, non-profit entities, and governments in the United States. Its products include sequential parallel comparison design (SPCD), a clinical trial design that reduces the detrimental impact of placebo response and addresses the placebo response problem by utilizing placebo non-responders; and SPCD comparative analysis software calculator that allows a sponsor of a trial to calculate the design parameters for an SPCD trial under sponsor-provided specifications, and to analyze and understand the efficiency of SPCD in comparison to a conventional trial. The company was founded in 2007

    • $10M to $50M annual revenues
    • 1-10 employees
    • $0.1M raised in June, 2013
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  14. grayscale photo of people in room


  15. Tigris Pharmaceuticals ($10M to $50M)

    Tigris Pharmaceuticals, Inc., a biopharmaceutical company, develops therapeutic technologies for oncology and other areas of unmet medical need. Its products include Aminoflavone that is for the treatment of renal cell, breast, and lung cancer; GGTI-2418, a synthetic peptidomimetic inhibitor of geranylgeranyltransferase, which is for the treatment of lung, breast, pancreatic, and ovarian cancer; GFB-204, a calixarene derivative that is a potent and selective inhibitor of VEGFR and PDGFR tyrosine phosphorylation, which is for the treatment of prostate, pancreas, lung, breast, and renal cell. The company was founded in 2005 and is based in Bonita Springs, Florida.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $6.5M raised in September, 2010
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  16. group of people sitting beside rectangular wooden table with laptops


  17. CoreRx ($10M to $50M)

    CoreRx™ is a contract pharmaceutical development organization that helps get products into the clinic faster, providing a complete spectrum of cGMP solutions for pharmaceutical dosage form development. Our wide range of support services, extensive instrumentation and rigorous quality systems provide timely results communicated in a clear, efficient and consistent manner.

    • $10M to $50M annual revenues
    • 101-250 employees
    • $3M raised in March, 2019
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  18. grey wooden table and black leather rolling chairs


  19. Tissuetech ($50M to $100M)

    TissueTech is an innovative technology company that uses products derived from human amniotic and umbilical cord tissues. Its medical technology platform markets innovative amniotic and umbilical cord-based products, thereby enabling physicians to avail of enhanced regenerative healing technology in eye care, wound care, and orthopedics. Tissuetech was founded in 2001 and is headquartered in Miami, Florida.

    • $50M to $100M annual revenues
    • 251-500 employees
    • $82.3M raised in June, 2019
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  20. brown wooden table and chairs


  21. Oragenics (Less than $1M)

    Oragenics are a biopharmaceutical company focused primarily on oral probiotics products and novel antibiotics for humans and companion pets. Within oral health we are commercializing our patented probiotic blend, ProBiora3® specifically formulated for oral health both under our branded Evora line and in private label configurations. Currently we have sales or contracts to sell these products in over 15 countries around the world. Our recent partnership with Intrexon in the field of Lantibiotics, a largely overlooked class of extremely potent gram-positive antibiotics, will help us to develop our pharmaceutical product candidate, MU1140-S™ and additional antibiotics from the Lantibiotic class for therapeutic use. The focus on the probiotic area will be to grow sales through a variety of channels including internet sales and the professional channel (dentists and hygienists) as well as through private label and bulk sales of our patented ProBiora3 blend. We intend to look for opportunities to expand our health claims for these products through a range of clinical studies. We are also looking at novel and convenient new delivery systems for our probiotics, which we plan to commercialize in the near future. In 2011 we received the Frost and Sullivan Award for excellence in probiotics. This was a competitive award that placed us as a leader in the probiotic space.

    • Less than $1M annual revenues
    • 11-50 employees
    • $21.9M raised in February, 2021
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  22. man in gray sweatshirt sitting on chair in front of iMac


  23. Accudial Pharmaceutical ($10M to $50M)

    AccuDial Pharmaceutical is comprised of two business units, which are AccuDial Pharmaceutical and Spinformation. AccuDial Pharmaceutical provides a variety of over-the-counter (OTC) and nutraceutical products for children and adults in liquid and pill form. The combined worldwide, total, addressable market for the AccuDial Pharmaceutical business units is approximately $3 billion. The Company utilizes its patented Spinformation label technology to differentiate AccuDial products from national and store brand manufacturers. Spinformation, established in 2000 by Stephen Key, developed and patented the Expanded Content Rotating Label technology. Spinformation increases the amount of printable space on a label of up to 75%. The technology is well suited for cosmetic, food, beverage, pharmaceutical, nutraceutical, and health and beauty markets. The labels can be applied to almost any bottle design and are useful for mail-in rebates, recipes, instant redeemable coupons, multiple language translations, and drug or nutrition facts. The labels can be printed with four-color process graphics. Although the company is privately owned it operates, discloses, and reports to its Shareholders as if it were a listed company.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $0.4M raised in November, 2014
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →




  24. Altor BioScience ($10M to $50M)

    Altor BioScience Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of immunotherapeutic agents for the treatment of cancer, viral infections, and autoimmune diseases. It offers STAR Fusion Reagents for diagnosing and targeting cancer and viral infections; and STAR Multimer Reagents for research and design of anti-cancer and anti-viral vaccine. The company's products in clinical stage include a monoclonal antibody that prevents and treats staphylococcal infections in premature neonates; and STAR-Ck or ALT-801, an anti-cancer drug. It also has products in various development stages, such as fusion agents for cancer and viral infections, immunotherapeutics against staphylococcal infections, gene therapy for cancer, and multimers reagents. In addition, the company provides products for detecting novel disease targets. Its products are used in the direct and quantitative detection of endogenous peptide antigens' presentation on diseased cells and tissues. The company was founded in 2002 and is headquartered in Miramar, Florida.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $30.3M raised in March, 2017
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  25. rectangular brown wooden table


  26. Dyadic International (Less than $1M)

    Dyadic International, Inc., is a global biotechnology company headquartered in Jupiter, Florida with its research and development center in the Netherlands. Dyadic uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceuticals and industrial enzyme industries. Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 fungus which enables the development and large scale manufacture of low cost enzymes and other proteins for diverse market opportunities. The C1 platform technology can also be used to screen for the discovery of novel genes and proteins. Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes which these technologies help produce

    • Less than $1M annual revenues
    • 51-100 employees
    • $2M raised in March, 2015
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →




  27. Ascendx Spine (Less than $1M)

    Ascendx Spine (formerly known as AOI Medical), a Winter Park, Florida-based medical device company focused on the development and commercialization of innovative orthopaedic devices for the spine and trauma markets.

    • Less than $1M annual revenues
    • 1-10 employees
    • $0.7M raised in May, 2012
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  28. two men using computers


  29. Sensus Healthcare ($1M to $10M)

    Sensus Healthcare is taking new aim at skin cancer. They're focused on the design, manufacture and marketing of products and services that incorporate proprietary mobile X-ray technology for cost-effective, non-invasive treatment of non-melanoma skin cancers. The signature Sensus Healthcare product, the SRT-100â„¢, meets stringent safety requirements set by the FDA, UL and ISO/CE Mark certification. Based in Boca Raton, FL, Sensus Healthcare employs best-practice standard operational procedures to ensure quality control, high-grade customer support, optimized success in field operations, and product reliability.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $15M raised in September, 2018
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  30. tennis table in room


  31. Integrity Implants (Less than $1M)

    Integrity Implants focuses in developing unique expandable interbody technology. The company's goal is to make the lives of customers better through advances in minimally invasive procedures. Integrity Implants constructs innovative technologies and products that can contribute to the enhancement of patient and hospital outcomes as it pertains to orthopedics and spine. Integrity Implants was founded 2016 and is headquarters Jupiter, Florida.

    • Less than $1M annual revenues
    • 11-50 employees
    • $4.1M raised in April, 2016
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  32. rectangular brown wooden table with chair lot inside building


  33. Procera ($10M to $50M)

    Established in 2005, Procera has become a leading cognitive health brand, developing and innovating around a line of products designed to support brain health. As a leader in the space, we believe very strongly in providing our customers with more than “just another supplement.” We want to educate people about the importance of maintaining cognitive health, the critical link between the mind and body, and the ways in which they can support their brain’s performance throughout their lives.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $0.5M raised in May, 2015
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  34. men using computers


  35. Halodine ($10M to $50M)

    Halodine is a biopharmaceutical company focused on the development of novel antiviral therapies. Halodine is a proprietary povidone-iodine antiseptic developed by leading clinicians for repeated nasal and oral administration. Halodine Nasal Antiseptic and Halodine Oral Rinse have been proven effective against SARS-CoV-2, the virus causing COVID-19, as well as other infections. Safe and easy-to-use, Halodine is designed to help protect hospitalized patients, health care personnel, and consumers. It was founded and is led by practicing MDs. Founded in 2020, the company is based in Miami, Florida.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $2.3M raised in June, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  36. people sitting in front of computer monitors


  37. Taronis Technologies ($1M to $10M)

    Taronis Technologies owns a patented plasma arc technology that enable two end use applications for fuel generation and water decontamination.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $25M raised in December, 2019
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  38. architectural photo of buildings during daytime


  39. Envoy Therapeutics (Less than $1M)

    Envoy Therapeutics’ mission is to discover new drugs with superior efficacy and fewer side effects than existing treatments. The company’s bacTRAP® technology enables the identification of proteins in vivo that are produced by specific cell types without requiring the isolation of those cells. The technology is especially powerful in tissues of the brain, where many hundreds of cell types are intermingled. Because therapeutically modulating the activity of a specific cell type has until now been prevented by the inability to determine which proteins are uniquely expressed by that cell type, Envoy brings a new day in drug discovery.

    • Less than $1M annual revenues
    • 11-50 employees
    • $1.2M raised in May, 2012
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  40. brown and white table and chairs


  41. Variant Pharmaceuticals (Less than $1M)

    Variant is a development stage specialty pharmaceutical company utilizing proprietary technologies to create and develop formulations that result in improved therapies for patients. With more than 120 years of biopharmaceutical industry expertise, the Variant team is focused on developing and commercializing products for the treatment of Men’s Health, as well as large and growing markets where current therapies are suboptimal or underdeveloped.

    • Less than $1M annual revenues
    • 1-10 employees
    • $10M raised in December, 2018
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  42. photo of industrial machines near table


  43. NeoGenomics Laboratories ($100M to $500M)

    NeoGenomics is a cancer reference laboratory that provides cancer testing and partnership programs to pathologists and oncologists.

    • $100M to $500M annual revenues
    • 501-1000 employees
    • $150M raised in December, 2016
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  44. two women sitting beside table using MacBooks


  45. BioMatrix Specialty Pharmacy ($1M to $10M)

    BioMatrix Specialty Pharmacy offers comprehensive, nationwide specialty pharmacy services and digital health technology solutions for patients with chronic, difficult to treat conditions. BioMatrix commitment to every patient is to provide individualized pharmacy services, timely access to care, and focused education and support. It offer a tailored approach for a wide range of therapeutic categories, improving health and empowering patients to experience a higher quality of life.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $80M raised in December, 2016
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  46. man and woman sitting at table


  47. Lakewood Amedex ($10M to $50M)

    Lakewood-Amedex is a biopharmaceutical company that focuses on developing novel-approach anti-infective products in the treatment of serious infectious diseases. The Company's products and technology are covered by an extensive patent portfolio consisting of 74 issued and 13 pending patents. It was founded in 2006 and headquartered in Sarasota, Florida.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $24.1M raised in January, 2021
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  48. selective focus photography of desk lamp on table


  49. BlinkBio ($1M to $10M)

    BlinkBio is a biotechnology company formed to exploit Bioorthogonal Linker (“BLink”) chemistries through their Tunable Drug Conjugates (TDCs) platform for the treatment of oncology and other diseases. It has assembled a modular toolbox of components allowing the design of Tunable Drug Conjugates a new class of Drug Conjugate therapies for the treatment of cancer. The company's TDC platform comprises a modular set of ligands, linkers, and payloads with aligned characteristics to enable both rapid payload release in the tumor and rapid systemic clearance of the parent drug conjugate. It was founded in 2009 and is headquartered in Jupiter, Florida.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $0.5M raised in May, 2019
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  50. man in black jacket sitting on chair


  51. Quantitative Medicine (Less than $1M)

    Quantitative Medicine's Computational Research Engine™ (CoRE™) is a dynamic and comprehensive in silico predictive modeling platform for constructing, assessing, validating and deploying exceedingly accurate predictive models to efficiently guide the testing process and solve complex drug discovery optimization problems. CoRE™ applies cutting edge machine learning techniques from three complementary informatics technologies: Supervised Learning, Transfer Learning and Active Learning, to efficiently solve multi-parameter optimization problems in a series of discrete discovery cycles. CoRE’s unique capability to effect simultaneous co-optimization of the entire efficacy, safety and off-target effects property profile is vastly more efficient than the standard approach and greatly accelerates discovery. Based on over 20 industry collaborations, it is very realistic to expect, at a minimum, CoRE™ can reduce preclinical attrition 5%, preclinical costs 20% and lead optimization costs 40%. When these three parameters were adjusted in a recent assessment of pharmaceutical R&D productivity (Paul et al. 2010 ) to capture the effects of using CoRE™, this translated to capitalized costs savings of $238 million and out-of-pocket cost reductions of $88 million. Additionally, CoRE™ can quickly yield significant reductions in time which may be instrumental in gaining first mover IP advantage, particularly with novel targets. The Revolutionary CoRE™ Platform Changes How Predictive In Silico Models Are Generated and Deployed, and How Highly Accurate Predictive Models Enable and Accelerate Efficient Drug Discovery. The net result is a game changing competitive advantage.

    • Less than $1M annual revenues
    • 1-10 employees
    • $0.2M raised in August, 2014
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  52. three women sitting around table using laptops


  53. Cantex Pharmaceuticals ($10M to $50M)

    Cantex Pharmaceuticals is a biotechnology company engaged in harnessing known therapies to develop novel and safer cancer treatments. Cantex is currently conducting two unique development programs with modified versions of two separate known chemical entities each of which addresses major unmet medical needs representing high-value market opportunities:

    • $10M to $50M annual revenues
    • 1-10 employees
    • $3.3M raised in April, 2014
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  54. people sitting and using laptops


  55. Coqui Radio Pharmaceuticals (Less than $1M)

    Coqui Radio Pharmaceuticals is a biopharmaceutical company that manufactures and supplies medical diagnostic and therapeutic radioisotopes. It aims to create a commercially scalable and reliable supply of medical diagnostic and therapeutic radioisotopes. Coquí Pharma is the only real solution for the impending Molybdenum-99 (Mo-99) crisis that is expected to occur in 2016 when several facilities shut down. The Coral Gables, Florida-based biopharma company was established by Carmen Irene Bigles in 2009.

    • Less than $1M annual revenues
    • 1-10 employees
    • $1M raised in August, 2013
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  56. men sitting of chair inside room


  57. VaxCare ($10M to $50M)

    VaxCare Corp. provides vaccination solutions for physicians, health systems, health departments, employers, and school systems. It offers SchoolCares, a school-located vaccine program toolkit; VaxStations, a technology-driven vaccination service for primary care providers; First-2-Know, a patient marketing and awareness solution that offers physicians an integrated phone, email, and text alert system to drive patient awareness and participation in the practice’s vaccination program; and EmployerCare, an onsite flu vaccination service for employers. The company was incorporated in 2006 and is based in Orlando, Florida.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $1.5M raised in October, 2012
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  58. people sitting on black chairs


  59. Cyclo Therapeutics (Less than $1M)

    Cyclo Therapeutics is a clinical-stage biotechnology company focused on the use of cyclodextrins in drug development. Cyclo Therapeutics (previously CTD Holdings) was organized as a Florida corporation on August 9, 1990, with operations beginning in July 1992. In conjunction with a restructuring in 2000, they changed their name from Cyclodextrin Technologies Development, or CTDI, to CTD Holdings. CTDI was then incorporated as a Florida corporation and became a wholly-owned subsidiary of CTD Holdings.

    • Less than $1M annual revenues
    • 1-10 employees
    • $2M raised in March, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  60. people sitting beside rectangular brown table with laptops


  61. Sincerus Pharmaceuticals ($10M to $50M)

    Sincerus Pharmaceuticals provides sterile and non-sterile pharmaceutical compounding services to physicians, group practices, surgery centers, and hospitals.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $0.5M raised in March, 2019
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  62. rolling armchair beside table


  63. Vector Vitale ($10M to $50M)

    Vector Vitale is creating a breakthrough class of therapeutic solutions that provide symmetry correction of biomolecules including amino acids, polypeptides, and proteins, and can be re-dosed to achieve a sustainable effect. They have put together a solid team of like-minded specialists with expertise in physics, chemistry, technology, and life sciences. It was founded in 2015 and headquartered in North Miami Beach, Florida.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $0.8M raised in January, 2017
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  64. people sitting on chairs near tables during daytime


  65. Progressive Care ($10M to $50M)

    Progressive Care Inc., through its subsidiary PharmCo, LLC, is a South Florida provider of prescription pharmaceuticals, which specializes in anti-retroviral patient management, long term care, and durable medical equipment (DME). The Company, is focused on developing the PharmCo brand and adding business elements that cater to specific under-served markets and demographics. This effort includes community and network based marketing strategies, introduction of new locations, acquisitions, and strategic collaborations with community, government, and charitable organizations.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $0.2M raised in December, 2011
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  66. people standiunmg


  67. American Injectables (Less than $1M)

    American Injectables is a sterile injectable manufacturer of parenteral drugs with a world-class facility focused on ready-to-use pre-filled syringes and vials.

    • Less than $1M annual revenues
    • 11-50 employees
    • $10M raised in September, 2020
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  68. people having meeting on rectangular brown table


  69. Accentia Biopharmaceuticals Inc ($10M to $50M)

    Accentia Biopharmaceuticals, Inc., a biotechnology company, primarily discovers, develops, and commercializes immunotherapies to treat autoimmune related diseases and cancer in the United States. The company develops Cyrevia as a system of care for various autoimmune diseases; BiovaxID as a personalized therapeutic cancer vaccine to treat non-Hodgkin’s lymphoma, follicular lymphoma, mantle cell lymphoma, and other B-cell cancers; and SinuNasal lavage system as a medical device for chronic sinusitis. It also manufactures and sells a range of cell culture systems used for the production cell culture products, including HF Primer, a cell culture system for producing small, research, and development quantities of cell culture products from mammalian cell lines; Multi-6 for producing six monoclonal antibodies; AutovaxID, an automated cell culture system for production of personalized cell-based treatments and various additional vaccines; Acusyst-miniMax system, which offers two single-use disposables options to meet various production requirements; Acusyst-Maximizer, a system for process development and routine productions; and Acusyst-Xcellerator, a production-scale cell culture system. In addition, the company manufactures mammalian cell culture products, such as whole cells, recombinant and secreted proteins, and monoclonal antibodies, as well as provides related services in developing cell production process protocols, cell line optimization, cell culture production optimization, media evaluation, and other related services. Further, it sells hollow fiber bioreactors, cultureware, tubing sets, and other disposable products and supplies. The company provides its cell culture products and services to biopharmaceutical and biotechnology companies, medical schools, universities, research facilities, hospitals, and public and private laboratories. Accentia Biopharmaceuticals, Inc. was founded in 2002 and is headquartered in Tampa, Florida.

    • $10M to $50M annual revenues
    • 51-100 employees
    • $0.4M raised in June, 2013
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  70. people using desktop computer inside office


  71. Health Integrated (Less than $1M)

    Health Integrated is the leading innovation partner for health plans, providing evidence-based solutions to accelerate the achievement of health management goals for clinical outcomes, quality measures, and cost containment. The company also offers care management, chronic conditions, transitions care, medical and behavioral utilization, physician review, payment integrity, analytics, and stratification. They leveraging big data to discover actionable insights to identify and engage the small percentage of members making the greatest impact on their plan members who would otherwise be overlooked.

    • Less than $1M annual revenues
    • 101-250 employees
    • $4M raised in June, 2014
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  72. grayscale photo of people in room


  73. Binder Biomedical (Less than $1M)

    Binder Biomedical, Inc. develops and supplies medical devices for the treatment of complex orthopedic and neurological spinal disorders. Its product portfolio focuses on applications for spine fusion surgery, including biologics. The company offers NEWTON Intervertebral Body Fusion System, a line of lumbar interbody spacers that include lumbar intervertebral body, anterior lumbar interbody, posterior lumbar intervertebral body, and transforaminal lumbar intervertebral body fusion devices. It also provides X-GRAFT, an interspinous allograft/donated human tissue; and cervical spacer, anterior lumbar spacer, and posterior lumbar spacer allografts designed to treat degenerative conditions of the spine. In addition, the company offers specialized implants that enable the maximization of disc height restoration and sufficient structural support while conforming to the anatomical requirements of the patient. It serves surgeons through sales agents and representatives in the United States and internationally. The company was founded in 2009 and is based in Boca Raton, Florida with an operations office in Miami, Florida.

    • Less than $1M annual revenues
    • 1-10 employees
    • $0.7M raised in April, 2012
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  74. group of people sitting beside rectangular wooden table with laptops


  75. Generex Biotechnology (Less than $1M)

    Generex Biotechnology Corporation, a development stage company, engages in the research, development, and commercialization of drug delivery systems and technologies for metabolic and immunological diseases. It develops a proprietary platform technology for the oral administration of large molecule drugs, including proteins, peptides, monoclonal antibodies, hormones, and vaccines. The company's products include Generex Oral-lyn, an insulin spray formulation used for the treatment of Type-1 and Type-2 diabetes; Glucose RapidSpray, which provides an alternative for people who require additional glucose in their diet, as well as delivers glucose formulation directly into the mouth; BaBOOM! Energy Spray, an instant energy spray designed to increase energy levels for sports, work, study, travel, and overall fatigue; and Crave-NX, a fat-free glucose spray that is used as an aid for dieters. Generex Biotechnology Corporation's under development products include medicinal chewing gum for the treatment of Type-2 diabetes mellitus and obesity; morphine and fentanyl products for breakthrough and postoperative pain; and AE37, an immunotherapeutic vaccine that is in Phase II clinical trials for patients with HER-2/neu positive breast cancer. The company markets its products through distributors and retail chains in Ecuador, Canada, and the United States. It has collaboration with Fertin Pharma A/S for the development of a metformin medicinal chewing gum. The company was founded in 1983 and is based in Toronto, Canada.

    • Less than $1M annual revenues
    • 51-100 employees
    • $0.8M raised in August, 2012
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  76. grey wooden table and black leather rolling chairs


  77. Dermal Life (Less than $1M)

    Dermal Life, LLC provides prescription and over-the-counter wound, burn, and skin care products for dermatologists, wound care centers, retail pharmacies, and consumer patients in the United States. The company was incorporated in 2009 and is based in Tampa, Florida.

    • Less than $1M annual revenues
    • 1-10 employees
    • $1M raised in June, 2011
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  78. brown wooden table and chairs


  79. MailMyPrescriptions.com (Less than $1M)

    MailMyPrescriptions.com®. Guaranteed low cash pay prices on over 1,400 FDA-approved generic drugs from our licensed US mail-order pharmacy. We do all the work – from obtaining your prescriptions from your physician or current pharmacy to providing clinical care over the phone, to shipping directly to your door. Your medications will usually arrive within 5 days from receipt of your prescriptions. No price shopping, discount coupons or trips to the pharmacy. You save up to 90% over retail pharmacy prices.

    • Less than $1M annual revenues
    • 51-100 employees
    • $1.6M raised in November, 2015
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  80. man in gray sweatshirt sitting on chair in front of iMac


  81. Evolugate ($10M to $50M)

    Evolugate is a biotechnology company that provides technology in the evolutionary optimization of micro-organisms. Using a patented technology, the company improves the bio conversion capabilities of yeasts, algae, fungi, and bacteria by adapting them to specific industrial settings and increasing their yield. Improved microbial strains have the capacity to positively impact the economics of several production processes based on biochemistry. Evolugate was established in 2005 and is headquartered in Gainesville, Florida.

    • $10M to $50M annual revenues
    • 11-50 employees
    • $0.2M raised in October, 2010
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →




  82. inCyte Innovations ($10M to $50M)

    inCyte Innovations, LLC was incorporated in 2010 and is based in Pembroke Pines, Florida.

    • $10M to $50M annual revenues
    • 501-1000 employees
    • $3M raised in July, 2010
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  83. rectangular brown wooden table


  84. Nanotherapeutics ($10M to $50M)

    Nanotherapeutics is a privately held specialty biopharmaceutical company with full product development, cGMP manufacturing capabilities, and a proprietary pipeline. The Company's technologies can be used with all drug types ranging from small molecules to proteins and peptides. These technologies can be employed with new chemical entities or with generic drugs and can be used with the spectrum of existing drug types ranging from small synthetic molecules to large recombinant macromolecules.

    • $10M to $50M annual revenues
    • 51-100 employees
    • $28.5M raised in March, 2015
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →




  85. Veloce BioPharma ($1M to $10M)

    Veloce BioPharma is a Florida based biotechnology company focused on the development of products for viral, fungal, and bacterial infections.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $2M raised in September, 2016
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  86. two men using computers


  87. Biscayne Pharmaceuticals ($1M to $10M)

    Biscayne Pharmaceuticals, Inc. operates as a biopharmaceutical company that develops therapies based on growth hormone-releasing hormone (GHRH) analogs. The compounds include GHRH antagonists in development for the treatment of cancer, including castrate-resistant prostate cancer, and GHRH agonists for the repair of cardiac damage in heart disease patients. The company was incorporated in 2012 and is headquartered in Miami, Florida.

    • $1M to $10M annual revenues
    • 11-50 employees
    • $3M raised in January, 2017
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  88. tennis table in room


  89. Jupiter Orphan Therapeutics ($1M to $10M)

    Jupiter Orphan Therapeutics, Inc. (JOT) is a specialty pharmaceutical company developing therapies for rare diseases linked to single gene deficiencies. JOT, a Delaware Corporation with it's principal office located in Jupiter, FL, USA, was founded in the summer of 2015. In its short period of operations, JOT has assembled a very strong management and scientific team as well as defined three pipeline products which of one is already in Phase II.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $2.5M raised in January, 2017
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  90. rectangular brown wooden table with chair lot inside building


  91. myMatrixx ($10M to $50M)

    myMatrixx is a full-service pharmacy and ancillary medical benefits management company. Our Technology Plus ™ platform and approach combines advanced technology, expert clinical support, productivity-improving processes, real-time alerts and comprehensive reporting to simplify the management of worker’s compensation claims. The result is a reduction of unnecessary costs and improved outcomes for our clients and their injured workers.

    • $10M to $50M annual revenues
    • 251-500 employees
    • $0.2M raised in May, 2010
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  92. men using computers


  93. UNO HEALTHCARE ($10M to $50M)

    UNO HEALTHCARE is a health care company based in Doral, Florida.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $2.3M raised in June, 2019
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  94. people sitting in front of computer monitors


  95. American Clinical Solutions ($1M to $10M)

    American Clinical Solutions is a leading provider of urine drug confirmation services, offering accurate testing for both prescription and illicit narcotics using the most advanced equipment available. Medical facilities and other healthcare providers rely on American Clinical to help ensure patient safety and maximize the benefits of prescription medicine use. ACS employs a unique, proprietary testing method with enhanced detection ability and improved accuracy which means physicians and other health care providers can prescribe with confidence. In addition to detecting improper use of prescribed and illicit drugs, ACS testing method helps healthcare providers monitor the efficacy of prescription regimens and alter the dosing scheme in response to changes in patient health status, behavior or other variables, helping patients achieve better outcomes while providing an overall greater level of safety. ACS techniques and technology were developed to meet or exceed the latest testing standards. Input from their physician colleagues provides invaluable guidance to help us refine their approach to ensure they continue to provide the best, most accurate testing results and reporting services available.

    • $1M to $10M annual revenues
    • 501-1000 employees
    • $10M raised in June, 2015
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  96. architectural photo of buildings during daytime


  97. Accu-Break Pharmaceuticals ($1M to $10M)

    ACCU-BREAK Pharmaceuticals, Inc. develops and licenses pharmaceutical tablet technologies. The company offers bi-layer and tri-layer technologies, which are used to create tablets that are dividable by hand into accurate partial/smaller doses for patients to adjust their dose. Its technologies are used for single drug products, fixed and split combination drug products, standard and controlled release formulations, and incompatible drugs in human and veterinary medicines. The company has a strategic alliance agreement with Azopharma Development Group. ACCU-BREAK Pharmaceuticals, Inc. was formerly known as SoLapharm, Inc. and changed its name to ACCU-BREAK Pharmaceuticals, Inc.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $1M raised in May, 2013
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  98. brown and white table and chairs


  99. Hansen Pharmaceutical (Less than $1M)

    Hansen Pharmaceutical offers proprietary technology that delivers gaseous nitric oxide under pressure to kill multi-drug resistant organisms. Since spinning out the technology and intellectual property in 2017, Hansen is building on the groundbreaking work started at Barry University’s Paul & Margaret Brand Research Center at the School of Podiatric Medicine.

    • Less than $1M annual revenues
    • 1-10 employees
    • $0.2M raised in November, 2014
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  100. photo of industrial machines near table


  101. BioCurity Pharmaceuticals (Less than $1M)

    BioCurity Pharmaceuticals is a biopharmaceutical company with a mission to transform a cancer patient’s recovery, by addressing a global unmet need for an effective treatment to mitigate radiation therapy toxicity. It is on track to fundamentally change the course of radiation therapy for cancer patients, worldwide. Approximately 6 million of the 18 million people who will be diagnosed with cancer every year, will receive radiation treatment. The lack of an effective treatment for the adverse side effects associated with radiation therapy represents a substantial market opportunity, but most importantly, a chance to help better the quality of life for cancer survivors around the world. BioCurity’s patented technologies and drugs in their pipeline have the potential to significantly reduce radiation toxicity, not just for newly diagnosed patients, but also for the millions of patients who must receive radiation as a part of their ongoing treatment for cancer.

    • Less than $1M annual revenues
    • 1-10 employees
    • $0.4M raised in June, 2020
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  102. two women sitting beside table using MacBooks


  103. Diverse Biotech (Less than $1M)

    Diverse Biotech, Inc is an innovative biopharmaceutical research company committed to discovering and developing novel therapies from its proprietary conjugate drug synthesis Platform. The company originated from oncologists adding cannabinoid therapy to standard of care treatment for cancer patients. The results were significant, unprecedented, and unpredicted. Based on the initial results, Diverse Biotech has taken the science and technology to the next level and put an experienced Executive Leadership Team in place to take the company forward.

    • Less than $1M annual revenues
    • 11-50 employees
    • $0.3M raised in March, 2019
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  104. man and woman sitting at table


  105. Enalare Therapeutics (Less than $1M)

    Enalare Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapies for patients suffering from acute respiratory and critical care conditions including respiratory depression caused by drug overdose, post-surgery, and pathogens.

    • Less than $1M annual revenues
    • 1-10 employees
    • $10M raised in February, 2021
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  106. selective focus photography of desk lamp on table


  107. Rothman Healthcare (Less than $1M)

    Rothman Healthcare Corporation develops electronic health record (EHR) solutions for hospital patient care applications. The company offers Patient Condition Tracker, a tool that implements graphical user interface for the Rothman Index for the visualization of data contained in the EHR; and generates a regularly updated health score based on vital signs, nursing assessments, and lab results in a graphical format. Its patient-centric software enables healthcare professionals to access patient health data. The company has a strategic partnership with Yale-New Haven Children's Hospital. Rothman Healthcare Corporation was founded in 2004 and is based in Pompano Beach, Florida.

    • Less than $1M annual revenues
    • 11-50 employees
    • $0.9M raised in July, 2012
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  108. man in black jacket sitting on chair


  109. TherapeuticsMD ($10M to $50M)

    TherapeuticsMD is a specialty pharmaceutical company focused on creating safe and effective branded and generic prescription, and over-the-counter products targeted exclusively for women. We are driven to pursue the development and commercialization of three advanced hormone replacement products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. These development candidates have received Investigational New Drug acceptance by the U.S. Food and Drug Administration

    • $10M to $50M annual revenues
    • 101-250 employees
    • $110M raised in February, 2021
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  110. three women sitting around table using laptops


  111. Nuovo Biologics (Less than $1M)

    Nuovo Biologics, L.L.C. engages in the research and development of animal health products. It develops PANAVIRA, an antiviral drug derived from natural sources that is used for the treatment of various viral related diseases in non-consumable animals, such as cats, dogs, birds, and horses. The company was incorporated in 2010 and is based in Miami, Florida.

    • Less than $1M annual revenues
    • 11-50 employees
    • $1M raised in April, 2011
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  112. people sitting and using laptops


  113. OPKO Health ($100M to $500M)

    OPKO Health, Inc. is a multi-national pharmaceutical and diagnostics company that aims to establish industry-leading positions in large and rapidly growing medical markets by leveraging its discovery, development, and commercialization expertise and its novel and proprietary technologies. The company intends to leverage its global commercialization expertise to pursue acquisitions of commercial businesses that will both drive growth and provide geographically diverse sales and distribution opportunities. OPKO has and may continue to make investments in other early stage companies that the company perceives to have valuable proprietary technology and significant potential to create value for OPKO as a shareholder.

    • $100M to $500M annual revenues
    • 501-1000 employees
    • $175M raised in February, 2013
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  114. men sitting of chair inside room


  115. Sancilio and Company ($1M to $10M)

    Sancilio & Company develops, manufactures, and distributes biopharmaceutical products in the United States and internationally. Its cardiovascular health products include OCEAN BLUE PROFESSIONAL OMEGA-3 2100, which is made from fish oils to decrease the risk of arrhythmias. The company also provides dental health products, including LUDENT SODIUM FLUORIDE CHEWABLE TABLETS that provide fluoride to the children; MVC MULTIVITAMIN WITH FLUORIDE CHEWABLE TABLETS, which contain vitamins and minerals; and sodium fluoride drops. In addition, it offers women’s health products, which include Mylk, a multivitamin/mineral/essential fatty acid softgel; and Caltranate, a blend of calcium formulated to control the release of calcium. Further, Sancilio & Company provides pharmaceutical services, such as analytical chemistry, dissolution testing, formulation development, de-formulation studies, HPLC, GC, GC/MS, and LC/MS support, raw material sourcing, contract tablet, capsule, and soft gel production, small-batch contract manufacturing, bottling/packaging, liquid filling of oral liquids, validation, product sales, and distribution and logistical support services. The company was founded in 2004 and is based in Riviera Beach, Florida with additional offices in Ohio and New Jersey.

    • $1M to $10M annual revenues
    • 101-250 employees
    • $20M raised in July, 2014
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  116. people sitting on black chairs


  117. Romark Laboratories ($10M to $50M)

    Romark Laboratories is a pharmaceutical company committed to the discovery, development and commercialization of innovative small molecules for treating infectious diseases and cancers

    • $10M to $50M annual revenues
    • 11-50 employees
    • $1.9M raised in July, 2014
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  118. people sitting beside rectangular brown table with laptops


  119. MATINAS BIOPHARMA ($1B to $10B)

    Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing therapeutics for the treatment of fungal and bacterial infections. The company develops orally delivered therapeutics based on a proprietary, lipid crystal drug delivery platform called cochleate delivery technology. Its lead product candidate is MAT 2203, an oral formulation of the broad spectrum anti-fungal drug amphotericin B that is in Phase II study for the treatment of fungal infections. The company is also involved in developing MAT2501, an orally-administered, encochleated formulation of amikacin for acute bacterial infections, including non-tuberculous mycobacterium (NTM) and multi-drug resistant gram negative bacterial infections. In addition, it is exploring development and partnership options for MAT9001, a prescription-only omega-3 fatty acid-based composition under development for hypertriglyceridemia; and MAT8800 discovery program, which intends to identify product candidates derived from omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease. Matinas BioPharma Holdings, Inc. was incorporated in 2013 and is based in Bedminster, New Jersey.

    • $1B to $10B annual revenues
    • 11-50 employees
    • $3.8M raised in November, 2020
    • 3 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  120. rolling armchair beside table


  121. RIST Neurovascular (Less than $1M)

    RIST Neurovascular is a healthcare company.

    • Less than $1M annual revenues
    • 1-10 employees
    • $1.3M raised in August, 2018
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  122. people sitting on chairs near tables during daytime


  123. Renibus Therapeutics ($10M to $50M)

    Renibus Therapeutics operates in the healthcare industry focusing on the pharmaceutical business. The company was incorporated in 2015 and is based in Lantana, Texas.

    • $10M to $50M annual revenues
    • 1-10 employees
    • $16.3M raised in September, 2019
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  124. people standiunmg


  125. Teewinot Life Sciences (Less than $1M)

    Teewinot Life Sciences is a global biopharmaceutical company focused on the biosynthetic production of pure pharmaceutical grade cannabinoids. Teewinot has developed patent protected processes for production of pure cannabinoids by means of biocatalysis and synthetic biology. Teewinot has also developed patent protected cannabinoid formulation technology all with the goal of improving human therapies. Headquartered in Tampa, Florida, Teewinot manufactures and licenses technology to make cost-effective and pharmaceutically pure cannabinoids. We are an industry leader in support of advancing medical research and product development. Teewinot’s global technology and intellectual property represent a breakthrough in the creation and delivery of cannabinoid-based medicines.

    • Less than $1M annual revenues
    • 11-50 employees
    • $12.3M raised in May, 2017
    • 2 founders
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  126. people having meeting on rectangular brown table


  127. Trxade Group ($1M to $10M)

    Trxade Group is a pharmaceutical company focused on solving real-world problems in healthcare. The company is providing efficient integrated pharmaceutical and medical services to pharmacies and consumers. It fosters price transparency and thereby improves profit margins for both buyers and sellers of pharmaceuticals. Trxade Group combines a web-based purchasing platform for supply chain transactions between independent pharmacies, drug distributors, and manufacturers. The company operates a specialty pharmacy, warehouse, and prescription delivery services for consumers throughout the US utilizing its proprietary Delivmeds mobile application (delivmeds.com), and multi-specialty telemedicine portal (bonumhealth.com) that enables efficient home delivery of patient care and medication. It was founded in 2010 and is headquartered in Land O Lakes, FL, USA.

    • $1M to $10M annual revenues
    • 1-10 employees
    • $1M raised in July, 2019
    • 1 founder
    • CEO Info & Email: Available in our premium reports 🔐
    • Likely to outsource: Available in our premium reports 🔐

    Visit Website →


  128. people using desktop computer inside office